Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with Recessive Dystrophic Epidermolysis Bullosa (MissionEB): a qualitative sub study of a randomised, double-blind, placebo controlled, crossover, phase 3 trial
Authors:
- Katie BiggsKBKatie Biggs
- Shamila DittaSDShamila Ditta
- Maria L. BagetaMBMaria L. Bageta
- Pablo Lopez-BalboaPLPablo Lopez-Balboa
- Rachel GloverRGRachel Glover
- Kate HutchenceKHKate Hutchence
- Diana PapaioannouDPDiana Papaioannou
- Steven JuliousSJSteven Julious
- Cindy CooperCCCindy Cooper
- Gabriela PetrofGPGabriela Petrof
- Anna E. MartinezAMAnna E. Martinez
Open Access
- 3 June 2026
- journal article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Abstract
Background: Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a rare genetic skin condition causing fragile skin, blistering, and scarring. It leads to chronic pain, slow wound healing, and severe limitations, profoundly impacting patient and family quality of life. Umbilical cord tissue-derived mesenchymal stromal cells (UC-MSC) have shown therapeutic promise. The Mission EB trial (ISRCTN14409785; registration date 25/03/2021) assessed UC-MSC safety and effectiveness in children with RDEB in a placebo-controlled, double-blinded, crossover study. Methods: This study used a qualitative research design with semi-structured interviews and thematic analysis, to explore Mission EB trial treatment impact on the quality of life of patients and parents. Parents and patients were interviewed at two time points (approximately 3- and 12-months post-randomisation). Purposive sampling included 10 parents and 6 children; 13 individuals (8 adults, 5 children) were interviewed twice (once in each study period). Interviews were transcribed verbatim, independently coded, with overall impressions agreed upon prior to unblinding. Results: RDEB significantly impacted daily life, marked by pain and itch. Participants were hopeful of the trial, willing to pursue minor improvements. UC-MSC infusions led to reduced pain/itchiness, improved wound healing, and resulted in fewer self-reported dressing changes. These benefits often translated to increased energy, improved eating, and greater daily activity participation. Benefits were more pronounced with active treatment. Negative effects were minimal, primarily venous access difficulties. Blinded participants could discern active UC-MSC from placebo based on symptom changes; 10 of 13 showed clear differences aligning with treatment. All parents interviewed expressed willingness for their child to receive treatment again. Conclusions: This qualitative research provides valuable insights into perceived benefits of UC-MSC treatment for children with RDEB. Interview findings regarding symptom improvement and participants’ ability to discern active treatment shed light on its perceived benefit in RDEB, especially in milder RDEB patients. The study highlights the critical importance of qualitative methodologies in adding to quantitative trial outcomes and capturing the meaningful impact of interventions on the lives of patients and families particularly where quantitative measures may not fully reflect lived experience.Keywords
Funding Information
- National Research Collaboration (NIHR127963)
- Cure EB (Cure EB)
This publication has 24 references indexed in Scilit:
- Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with recessive dystrophic epidermolysis bullosa (MissionEB): a randomised, double-blind, placebo controlled, crossover, phase 3 trial with an internal phase 1 dose de-escalation phaseeClinicalMedicine, 2025
- Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosaBritish Journal of Dermatology, 2024
- Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosaHuman Immunology, 2024
- Advances in Treatments for Epidermolysis Bullosa (EB): Emphasis on Stem Cell-Based TherapyStem Cell Reviews and Reports, 2024
- Heterogeneity of reported outcomes in epidermolysis bullosa clinical research: a scoping review as a first step towards outcome harmonizationBritish Journal of Dermatology, 2023
- Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional surveyJournal of the American Academy of Dermatology, 2021
- Epidermolysis bullosaNature Reviews Disease Primers, 2020
- Quality of life in people with epidermolysis bullosa: a systematic reviewQuality of Life Research, 2020
- Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis BullosaJournal of Investigative Dermatology, 2015
- The clinical spectrum of dystrophic epidermolysis bullosaBritish Journal of Dermatology, 2002